Synapse - Lee Krug

Results (15)

Export to EndNote / Excel | PubMed

GM2, fucosyl GM1, globo H and polysialic acid are suitable targets for a tetravalent vaccine against SCLC

Meeting Abstract

Livingston, P.; Hood, C.; Krug, L. M.; Warren, N.; Kris, M. G.; Brezicka, T.; Ragupathi, G.
Cancer Research (2005)

Fulltext@MSK | Save

Pilot study of GD2 synthase transcript levels in small cell lung cancer (SCLC)

Meeting Abstract

Chen, L. C.; Cheung, I. Y.; Jones, J.; Kris, M. G.; Cheung, N. K. V.; Krug, L. M.
Cancer Research (2005)

Fulltext@MSK | Save

Hemithoracic radiation therapy and brachytherapy after pleurectomy/decortication for malignant pleural mesothelioma: Results from a 30-year experience

Meeting Abstract

Rosenzweig, K. E.; Gupta, V.; Mychalczak, B.; Krug, L. M.; Flores, R.; Rusch, V. W.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

Phase I/II trial of gefitinib and RAD001 (everolimus) in patients (pts) with advanced non-small cell lung cancer (NSCLC)

Meeting Abstract

Milton, D. T.; Kris, M. G.; Azzoli, C. G.; Gomez, J. E.; Heelan, R.; Krug, L. M.; Pao, W.; Pizzo, B.; Rizvi, N. A.; Miller, V. A.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

A multicenter phase 2 trial of neo-adjuvant pemetrexed plus cisplatin (PC) followed by extrapleural pneumonectomy (EPP) and radiation (RT) for malignant pleural mesothelioma (MPM)

Meeting Abstract

Krug, L. M.; Pass, H. I.; Rusch, V. W.; Sugarbaker, D. J.; Rosenweig, K. E.; Friedberg, J. S.; Bloss, L. P.; Ye, Z.; Obasaju, C. K.; Vogelzang, N. J.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

Hu3S193, a humanized monoclonal antibody directed against Lewis Y, demonstrates strong targeting to small cell lung cancer (SCLC) in patients

Meeting Abstract

Krug, L. M.; Milton, D. T.; Chen, L. C.; Jungbluth, A. A.; Nagel, A.; Finn, R.; Pandit-Taskar, N.; Jones, J.; Divgi, C.
Clinical Cancer Research (2005)

Fulltext@MSK | Save

Gemcitabine/cisplatin plus bevacizumab or placebo in advanced malignant mesothelioma: A multi-center, double-blind, placebo-controlled, randomized phase III trial

Meeting Abstract

Kindler, H.; Lu, C.; Gandara, D.; Stevenson, J.; Krug, L.; Janne, P.; Gitlitz, B.; Karrison, T.; Stadler, W.; Vokes, E.
Lung Cancer (2005)

Fulltext@MSK | Save

A multicenter, double-blind, placebo-controlled randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo in patients (pts) with malignant mesothelioma (MM)